Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older who have been diagnosed with a specific type of breast cancer (hormone receptor-positive, HER2-negative) that has spread to other parts of the body (confirm with trial site for exact diagnosis details).
- People currently being treated with a medicine called Palbociclib combined with certain hormone-blocking medicines (such as letrozole, exemestane, anastrozole, or fulvestrant), either as a first, second, or later treatment for their advanced breast cancer.
- People who may also be using ovarian suppression treatment if they have not yet gone through menopause.
- People who have already been on their current Palbociclib and hormone therapy for at least 3 months.
- People who are willing and able to sign an informed consent form, either on paper or digitally, showing they understand what the study involves.
- People who agree not to take part in any other clinical trial involving a medication while participating in this study.
- People with a certain level of physical functioning, as measured by a standard medical scale called the ECOG performance status (confirm with trial site for the required score).
- People who have access to a compatible smartphone and a 3G or 4G mobile internet connection.
Who may not be able to join:
- People with serious uncontrolled medical conditions, such as uncontrolled heart rhythm problems, a heart attack within the past 6 months, a recent stroke, uncontrolled bleeding in the digestive system, or an active uncontrolled infection.
- People with a psychiatric condition that would prevent them from being able to give informed consent.
- People whose doctors estimate they have less than 3 months to live.
- People who have taken part in another clinical trial involving an investigational (experimental) medicine within the past 28 days.
- People with another serious medical, psychiatric, or laboratory condition that, in the opinion of the trial doctor, could put them at greater risk or make the study results harder to interpret.
- People who are unable to read, or whose level of education may make it difficult to use the study's smartphone application or a physical activity monitoring watch.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Graziela Dal Molin, MD, Beneficência Portuguesa de São Paulo
Phone: 11-35052639
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast; Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast; Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast; Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.